THE ONLY 8-WEEK
PANGENOTYPIC CURE¹*In treatment-naïve, non-cirrhotic
and compensated cirrhotic HCV patients

Integrated, pooled analysis of GT 1-6, TN adult participants with chronic HCV, treated for 8 weeks, from 8 phase 2/3, open-label clinical trials. The primary endpoint of each study was SVR12.³

ENDURANCE-1^1,4
GT 1, TN or PRS-TE, NC participants (± HIV-1 coinfection) were randomized to receive MAVYRET for 8 (n=351) or 12 (n=352) weeks.

ENDURANCE-3^1,4
GT 3, TN, NC participants were randomized (2:1) to receive MAVYRET (n=233) or SOF + DCV (n=115) for 12 weeks; additional participants (n=157) were subsequently enrolled and nonrandomly assigned to receive MAVYRET for 8 weeks.

ENDURANCE-5,6^1,5
GT 5-6, TN or PRS-TE, NC or CC participants (n=84) received MAVYRET for 8 (n=75) or 12 (n=9) weeks.

EXPEDITION-2^1,6
GT 1-6, TN or PRS-TE, NC or CC participants with HIV-1 and ART naïve or on a stable ART regimen received MAVYRET for 8 (n=137) or 12 (n=16) weeks. Treatment-experienced GT 3–infected participants were excluded.

EXPEDITION-5⁷
GT 1-6, TN or PRS-TE, NC or CC participants with CKD stage 3b, 4, or 5 received MAVYRET for 8 (n=84), 12 (n=13), or 16 (n=4) weeks.

EXPEDITION-8^1,8
GT 1-6, TN, CC participants (n=343) received MAVYRET for 8 weeks.

SURVEYOR-1, PART 2 (PHASE 2)^9,10
GT 1 and 4-6, TN or PRS-TE, NC or CC participants received MAVYRET for 8 (n=117) or 12 (n=332) weeks.

SURVEYOR-2, PARTS 2 AND 4 (PHASE 2)^1,11-13
GT 2-6, TN or PRS-TE, NC or CC participants were randomized to receive MAVYRET for 8 (n=286), 12 (n=48), or 16 (n=4) weeks.

METHODOLOGY^1,14
A phase 3b, multicenter, single-arm, open-label study evaluated the efficacy and safety of 8-week treatment with MAVYRET in participants (N=286) with acute HCV infection; adults and adolescents aged ≥12 years with GT 1-6, who were NC or CC, and TN for the current infection, were eligible to enroll. The primary endpoint was SVR12.

INCLUSION CRITERIA¹
Diagnosis of acute HCV infection at screening was based on physician diagnosis, quantifiable HCV RNA, and one or more of the following: negative anti-HCV antibody, recent conversion of negative to positive results in anti-HCV antibody, HCV RNA or HCV core antigen testing, liver disease signs associated with acute HCV infection, and recent risk behaviors for HCV infection.

SELECT BASELINE CHARACTERISTICS¹

• Median age, 43 years (range, 20-78) 
• History of prior HCV infection (18%) 
• HCV GT 1 (58%), GT 2 (4%), GT 3 (12%), GT 4 (17%)
• Cirrhosis (2%)
• HIV coinfection (50%)
• Current/recent PWID (14%) 
• Ongoing use of MAT for opioid use disorder (7%)